Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Hemorheol Microcirc ; 36(1): 13-23, 2007.
Article in English | MEDLINE | ID: mdl-17211058

ABSTRACT

BACKGROUND: Conflicting results were reported about the efficacy of vitamin E (E) treatment in porphyria cutanea tarda (PCT). We conducted a study in PCT patients to investigate whether E treatment has any additional beneficial effects compared with phlebotomy (P) treatment alone on rheological and oxidative stress parameters. METHODS: Twenty three patients with sporadic PCT in clinical remission and 10 healthy control patients were studied. All patients were treated with P prior to the study until clinical remission was achieved. Baseline routine laboratory [blood glucose, serum lipids, C-reactive protein (CRP), iron metabolism indices, liver function tests], oxidative stress [serum thiobarbituric acid reactive substances (TBARS), plasma H-donor activity, plasma free SH-groups, erythrocyte glutathion peroxidase activity] and rheological parameters (whole blood and plasma viscosity, cell transit time, clogging rate) were measured in both groups. Then all PCT patients received E (tocopherol acetate) 200 mg/day for 8 weeks and at the end of treatment measurements identical to those performed at baseline were repeated. RESULTS: Increased urine uroporphyrin, serum CRP, TBARS concentrations, whole blood and plasma viscosity and decreased plasma H-donor activity, free SH-group level, erythrocyte glutathione peroxidase activity were detected in PCT patients treated with P alone compared with control group consistent with residual oxidative stress in PCT patients. E treatment decreased urine uroporphyrin and serum TBARS concentrations; increased plasma H-donor activity and did not influence whole blood and plasma viscosity compared with P treatment alone. CONCLUSIONS: E treatment reduced the residual oxidative stress and did not influence increased plasma and whole blood viscosity present in PCT patients receiving P treatment prior to clinical remission.


Subject(s)
Antioxidants/therapeutic use , Hemorheology/drug effects , Phlebotomy , Porphyria Cutanea Tarda/therapy , Vitamin E/therapeutic use , Adult , Aged , Aged, 80 and over , Alanine Transaminase/blood , Antioxidants/administration & dosage , Antioxidants/pharmacology , Aspartate Aminotransferases/blood , Blood Glucose/analysis , Blood Viscosity/drug effects , C-Reactive Protein/analysis , Erythrocyte Deformability/drug effects , Feces/chemistry , Female , Ferritins/blood , Glutathione Peroxidase/blood , Homeostasis/drug effects , Humans , Lipids/blood , Male , Middle Aged , Oxidation-Reduction/drug effects , Oxidative Stress/drug effects , Porphyria Cutanea Tarda/blood , Porphyria Cutanea Tarda/drug therapy , Porphyria Cutanea Tarda/urine , Porphyrins/blood , Thiobarbituric Acid Reactive Substances/analysis , Uroporphyrins/urine , Vitamin A/blood , Vitamin E/administration & dosage , Vitamin E/blood , Vitamin E/pharmacology , gamma-Glutamyltransferase/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...